Other News

EBR Systems nominated for MTAA Excellence in Medical Technology award

SUNNYVALE, Calif., Oct. 23, 2023 /PRNewswire/ — EBR Systems, Inc. (ASX:EBR), the developer of the world’s only wireless cardiac pacing device for heart failure, is pleased to announce it has been named as a nominee for the 2023 Medical Technology Association of Australia (MTAA) Kerrin Rennie award. This nomination by the MTAA recognizes the potential of EBR Systems’ […]

Genesis MedTech initiates enrolment in its North American Early Feasibility Study using the J-Valve™ Transfemoral System for patients with severe aortic regurgitation

BURLINGAME, Calif., Oct. 23, 2023 /PRNewswire/ — Genesis MedTech, a leading medical device company, today announced initiation of enrolment in its North American Early Feasibility Study using its dedicated TAVR system, J-Valve™ Transfemoral (TF) System. The procedure was successfully performed by Dr. Dean Kereiakes, MD, Dr. Santiago Garcia, MD, and the team at The Lindner […]

Mindray Expands Its Cardiac Biomarker Portfolio with Cutting-Edge hs-cTnI and NT-proBNP Assays, Empowering Enhanced Cardiovascular Diseases Care

SHENZHEN, China, Oct. 23, 2023 /PRNewswire/ — Mindray (SZSE: 300760), a global leader in medical devices and solutions, introduces high-sensitivity troponin I (hs-cTnI) and NT-proBNP cardiac biomarkers. The additions have enhanced Mindray’s diverse portfolio of cardiac biomarkers for cardiovascular diseases (CVDs) diagnosis and management. While CVDs are the leading cause of death […]

Medtronic receives FDA approval for extravascular defibrillator to treat abnormal heart rhythms, sudden cardiac arrest

DUBLIN, Oct. 23, 2023 /PRNewswire/ — Medtronic plc (NYSE:MDT), a global leader in healthcare technology, has received U.S. Food and Drug Administration (FDA) approval for the Aurora EV-ICD™ MRI SureScan™ (Extravascular Implantable Cardioverter-Defibrillator) and Epsila EV™ MRI SureScan™ defibrillation lead to treat dangerously fast heart rhythms that can lead to sudden cardiac […]

Advanced Bifurcation Systems Inc. Receives FDA Breakthrough Device Designation

LIVERMORE, Calif., Oct. 23, 2023 /PRNewswire/ — Advanced Bifurcation Systems Inc. (ABS), a pioneer in comprehensive solutions for bifurcation lesions in coronary angioplasty, today announced that it has received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its novel coronary artery bifurcation stenting technology. This prestigious designation […]

Philips supports Tampere Heart Hospital in Finland to decarbonize its clinical operations

October 19, 2023 Sustainability roadmap addresses opportunities to reduce carbon emissions in patient throughput, technology use, and use of consumables Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the completion of a comprehensive hospital-wide analysis of Tampere Heart Hospital – […]

Cardio Flow, Inc., Announces U.S. Food and Drug Administration (FDA) 510(k) Clearance for its FreedomFlow® Orbital Atherectomy Peripheral Platform

ST. PAUL, Minn.–(BUSINESS WIRE)–Cardio Flow, Inc., a privately held medical device company and developer of minimally invasive devices to treat peripheral artery disease (PAD), today announced it recently received U.S. Food and Drug Administration (FDA) 510(k) clearance for the company’s FreedomFlow Orbital Atherectomy Peripheral Platform. “Critical Limb Ischemia: Volume 1. […]

Walgreens and the Cardiovascular Research Foundation Unite to Improve Recognition and Diagnosis of Valvular Heart Disease for Older Americans

DEERFIELD, Ill. & NEW YORK–(BUSINESS WIRE)–Walgreens and the Cardiovascular Research Foundation (CRF) today announced a collaboration to drive forward the PREVUE-VALVE study, a groundbreaking population-based clinical trial that aims to quantify the prevalence of valvular heart disease (VHD) among older Americans and pave the way for the development of new […]

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

CAMBRIDGE, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for NTLA-2001 for the […]